Medicine
Increlex 40 mg/4 mL injection
Increlex 40 mg/4 mL injection is a prescription medicine containing Mecasermin for subcutaneous use, marketed by Ipsen Biopharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Keep refrigerated and use within 30 days of initial vial entry.
Key facts
- Active ingredient (INN)
- Mecasermin
- Brand
- Increlex
- Strength
- 40 mg/4 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 4 mL
- Marketing authorisation holder
- Ipsen Biopharmaceuticals
- Manufacturers
- Ipsen BiopharmaceuticalsEton Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Keep refrigerated and use within 30 days of initial vial entry.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01AC03 Mecasermin
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 January 2006
- Identifiers
- RxCUI 604806, 615882DailyMed set ID a8b27a1b-a611-4f91-ad22-76d4b390c3ae, d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbceNDC 15054-1040, 71863-216Application BLA021839
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, multi-dose in 1 carton / 4 mL in 1 vial, multi-dose | 15054-1040-5 | Ipsen Biopharmaceuticals | 3 January 2006 |
| 1 vial, multi-dose in 1 carton / 4 mL in 1 vial, multi-dose | 71863-216-04 | Eton Pharmaceuticals | 16 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Mecasermin is a prescription medicine indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF- 1 deficiency or with growth hormone (GH) gene deletion. MedsAcross supplies Mecasermin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MecaserminFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Increlex prescribing information (Eton Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Increlex: European public assessment report (EPAR) · European Medicines Agency
Need Increlex 40 mg/4 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.